Latest Neurizon Therapeutics News & Updates

See the latest news and media coverage for Neurizon. We track all announcements, press releases, and industry mentions in real time, all in one place.

Neurizon Therapeutics (Neurizon)

Biotechnology company developing neurodegenerative disease treatments

neurizon.com

Headquarters: Melbourne, Australia
Company type: Public company
Number of employees: 2–15

Last updated Today

Latest news about Neurizon Therapeutics (Neurizon)

In short: Neurizon Therapeutics secured drug supply and licensing deals with Elanco and surpassed the 50% dosing milestone for its HEALEY ALS Platform Trial.

Company announcements

June 16 Neurizon

Neurizon signs supply agreement with Elanco

The long-term agreement secures GMP monepantel for NUZ-001, strengthening commercial and regulatory foundations.

June 12 Neurizon

Neurizon announces dosing milestone in ALS trial

Over 50% of participants in Regimen I of the HEALEY ALS Platform Trial have been dosed for NUZ-001.

May 8 Neurizon

Neurizon Therapeutics welcomes Dr Ross Murdoch as Independent Non-Executive Director

His extensive experience strengthens the Board for clinical execution and growth. The company thanks Dr Michael Thurn for his contributions.

April 1 Neurizon

Neurizon Therapeutics announces new preclinical data on NUZ-001

NUZ-001 increases activity in protein clearance pathways like autophagy and proteasomal system in neuronal models. Findings support its profile for ALS treatment in HEALEY trial.

Media coverage

June 12 The Australian

Neurizon ALS platform trial passes 50pc dosing milestone ahead of schedule

Neurizon Therapeutics has announced more than half of the planned 240 participants in Regimen I of its ALS platform trial ...

May 27 The Australian

Neurizon ALS trial expands cohort to 240 patients as enrolment accelerates

Neurizon Therapeutics will increase its total patient cohort in Regimen I of the ALS Platform Trial from 160 to 240, with strong recruitment momentum accelerating...

May 19 FinanzNachrichten

Neurizon Therapeutics Limited: Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001

Neurizon ® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing...

May 18 ALS News Today

Neurizon gets OK to test liquid form of ALS medication in Australia

Neurizon received approval for a Phase 1 trial of liquid NUZ-001 for ALS in Australia. This liquid form addresses swallowing difficulties common in ALS patients...

Never miss news about Neurizon

Track Neurizon and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Neurizon competitors & trending companies

Browse news for competitors to Neurizon and other trending companies.